Altamira Therapeutics (formerly Auris Medical) said that the European Patent Office (EPO) has issued a notice that it will grant a patent (No. 3698791) covering the company's AM-125 intranasal formulation of betahistine until February 2038. Altamira says that it has been granted composition of matter and methods of use patents for intranasal betahistine in 50 … [Read more...] about Altamira gets European patent for intranasal betahistine
Business
Inhalon Biopharma licenses human metapneumovirus antibodies for inhaled delivery
Inhalon Biopharma announced that it has licensed human metapneumovirus (hMPV) antibodies from the University of Georgia and intends to develop inhaled hMPV antibodies for the treatment of hMPV respiratory infections. According to the company's website, its pipeline includes a candidate designated IN-003 against hMPV. Inhalon's pipeline of inhaled therapies based … [Read more...] about Inhalon Biopharma licenses human metapneumovirus antibodies for inhaled delivery
Transpire Bio opens new headquarters and research facility
Transpire Bio, which launched in 2022 to develop inhaled therapeutics for both local and systemic delivery, has officially opened its new headquarters and research facility in Weston, FL, USA. Shortly after launching, the company announced deals with Recipharm for development of 4 inhaled formulations (TRB-1, TRB-2, TRB-3, and TRB-4) and with INTO for 3 additional … [Read more...] about Transpire Bio opens new headquarters and research facility
MannKind gets US patent covering clofazimine inhalation suspension
According to MannKind Corporation, the United States Patent and Trademark Office (USPTO) has issued US patent No. 11,793,808 ("Compositions of Clofazimine, Combinations Comprising Them, Processes for Their Preparation, Uses and Methods Comprising Them"), which covers the company's MNKD-101 clofazimine inhalation suspension, until 2039. MannKind is developing MNKD-101 … [Read more...] about MannKind gets US patent covering clofazimine inhalation suspension
Qnovia partners with University of Virginia for development of inhaled antimicrobial peptides
Qnovia (formerly Respira Technologies) has announced a partnership with researchers at the University of Virginia (UVA) for the development of two new antimicrobial peptides for delivery via the company's RespiRx vibrating mesh nebulizer technology. The new candidates will be called QN-05, which will be developed for the treatment of pneumonia, and QN-06, for the … [Read more...] about Qnovia partners with University of Virginia for development of inhaled antimicrobial peptides
Akita Biosciences launches Profi antiviral nasal spray
Startup Akita Biosciences, newly launched by faculty members of Brigham & Women's Hospital to develop intranasal therapies, has announced the availability of its first nasal product. The company says that Profi prophylactic nasal spray is "a drug-free formulation composed predominantly of ingredients that have previously been used intranasally at doses higher than … [Read more...] about Akita Biosciences launches Profi antiviral nasal spray
Oragenics to acquire Odyssey Health’s nasal delivery technology
Oragenics will acquire Odyssey Health's breath-powered intranasal delivery device and dry powder nasal formulations, in a deal that includes 8 million shares of Oragenics Series F preferred stock and a total of $1 million in cash, the companies said. The drugs included in the deal are Odyssey's OPN-002 for the treatment of mild traumatic brain injury and ONP-001 for … [Read more...] about Oragenics to acquire Odyssey Health’s nasal delivery technology
Codagenix gets BARDA funding for Phase 2b trial of CoviLiv intranasal vaccine against COVID-19
According to Codagenix, the US Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) will provide up to $389 million to support a Phase 2b trial of CoviLiv live attenduated intranasal vaccine as a booster. Under the contract, the first tranche provided by BARDA will be $10 million. Codagenix is developing CoviLiv in … [Read more...] about Codagenix gets BARDA funding for Phase 2b trial of CoviLiv intranasal vaccine against COVID-19
Avalyn Pharma raises $175 million for continued development of AP01 inhaled pirfenidone and AP02 inhaled nintedanib
Avalyn Pharma announced that an oversubscribed Series C financing brought in $175 million that the company will use for continued development of AP01 inhaled pirfenidone and AP02 inhaled nintedanib for the treatment of pulmonary fibrosis. Earlier this year, the company reported data from a Phase 1b trial of nebulized AP01 in patients with idiopathic pulmonary fibrosis … [Read more...] about Avalyn Pharma raises $175 million for continued development of AP01 inhaled pirfenidone and AP02 inhaled nintedanib
CF Foundation to provide an additional $9 million for development of Arcturus’ ARCT-032 inhaled mRNA therapy
The Cystic Fibrosis Foundation announced that it has agreed to provide an additional $9 million in funding for development of Arcturus Therapeutics' ARCT-032 inhaled mRNA therapy for the treatment of CF. The CF Foundation said that it has already provided $15.6 million for development of ARCT-032, which is based on Arcturus' LUNAR lipid nanoparticle delivery platform. … [Read more...] about CF Foundation to provide an additional $9 million for development of Arcturus’ ARCT-032 inhaled mRNA therapy